Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10:1595–622.

Article  PubMed  PubMed Central  Google Scholar 

Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11:2757–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, et al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2022;13:847–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43:501–11.

Article  CAS  PubMed  Google Scholar 

Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina (Kaunas). 2023;59:182.

Article  PubMed  Google Scholar 

Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline. NG28. 2022.

Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022, a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

IQVIA. Longitudinal prescription data: SGLT2 inhibitor prescribing data for England. 2023.

Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12: e230005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans M, Morgan AR, Bain SC, Davies S, Dashora U, Sinha S, et al. Defining the role of SGLT2 inhibitors in primary care: time to think differently. Diabetes Ther. 2022;13:889–911.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alder A. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. UKPDS perspective, legacy effects and 44-year follow-up data [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https://www.easd.org/media-centre/#!resources/ukpds-perspective-legacy-effects-and-44-year-follow-up-data. Accessed 14 Mar 2024

Holman RR. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. Clinical outcomes at 44 years: do the legacy effects persist? [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https://www.easd.org/media-centre/#!resources/clinical-outcomes-at-44-years-do-the-legacy-effects-persist. Accessed 14 Mar 2024

Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11:2465–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8: e012356.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.

Article  CAS  PubMed  Google Scholar 

Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144:1284–94.

Article  PubMed  PubMed Central  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction. Circulation. 2021;143:326–36.

Article  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–75.

Article  CAS  PubMed  Google Scholar 

Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24:1072–83.

Article  CAS  PubMed  Google Scholar 

Gonzalez Perez A, Vizcaya D, Sáez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care. 2023;11: e003072.

Article  PubMed  PubMed Central  Google Scholar 

Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310–30.

Article  CAS  PubMed  Google Scholar 

Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1–10.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35.

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.

Article  CAS  PubMed  Google Scholar 

The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–27.

Article  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1-127.

Google Scholar 

Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022;16:223–44.

Article  CAS  PubMed  Google Scholar 

Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6: e009417.

Article  PubMed  PubMed Central  Google Scholar 

Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–94.

Article  CAS  PubMed  Google Scholar 

Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801.

Article  Google Scholar 

Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22:195.

Article  PubMed  PubMed Central  Google Scholar 

Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271–82.

Article